AEG Electrolux COMPETENCE 5133 V User Manual Page 28

  • Download
  • Add to my manuals
  • Print
  • Page
    / 82
  • Table of contents
  • BOOKMARKS
  • Rated. / 5. Based on customer reviews
Page view 27
Results: Potential GvL anti
g
ens
g
Established leukemia-antigens
e.g.: PRAME, RHAMM…
Expertise in allo-restricted TCR isolation
(HLA-B7-restricted MPO-pepitde)
Before
stimulation
After
stimulation
TCR-isolation
and -transfer
Novel leukemia-antigens:
e.g.: MPO, ELANE, MYB…
(Klar et al
Leukemia
in
revision
)
11 1%
1.5% 45.8%
41 6%
CD8
0.0%
0.2%
Before
stimulation
After
stimulation
H
LA multimer
MPO
5
(Klar
et
al
.
Leukemia
in
revision
)
HLA-restrictions:
11
.
1%
41
.
6%
HLA multimer MPO
5
H
CD8
Lymphocy tes untransduced
L h t TCR2 5D6 t d d
Antigen specificity
Lymphocytes untransduced
LhtTCR25D6tdd
Leukemia reactivity
HL
A
-A*01 HL
A
-B*0
7
HLA-A*02 HLA-B*08
HL
A
-A*0
3
HL
A
-B*1
5
200
400
600
800
1000
2000
3000
L
ymp
h
ocy
t
es
TCR2
.
5D6
-
t
rans
d
uce
d
IFN-
(pg/ml )
400
600
800
1000
4000
L
ymp
h
ocy
t
es
TCR2
.
5D6
-
t
rans
d
uce
d
IFN-
(pg/ml )
MPO
B7
++ ++ ++-
++ ++ +-+
HLA-A*11 HLA-B*18
HLA-A*24 HLA-B*44
C1R-B7
C
1
R
-
B7
/
MP
O
5
C1R
-B7/
MP
O +
MP
O
BJ
A
B-B7
BJAB-B7/MPO
5
BJAB
-
B7/MPO
+
MP
O
0
MPN
1
5
M
P
N1 + MPO
M
PN2
5
M
PN2 + M
PO
M
PN3
5
MPN3 + MPO
MP
N5
5
MPN5 + MPO
MPN
6
5
MPN6 + MPO
AML2
5
AM
L2
+ M
P
O
AM
L6
5
AM
L6
+
MP
O
0
200
Klar et al. Leukemia in revision
www.m4.de
Innovationsleistun
g
/
Nachhalti
g
keit
g
g
Characterization of GvL T cells in the beneficial ATIR™ product
Isolation of leukemia reactive T cells and TCR
Phase III study with ATIR™ in context of haploidentical stem cell
transplantations
Clinical studies with leukemia-reactive, TCR-transgenic ATIR™
Improvement of therapy of leukemia-patients with haplo-identical SCT
1. Reduction of GvHD b
y
de
p
letion of allo-reactive T cells
yp
2. Induction of GvL effect by transduction of ATIR™ with leukemia-
reactive TCRs
www.m4.de
ReversibleStreptamer‐ReagenzienfürklinischeZelltherapie
Streptamer basierteCellAffiniTyCHromatography(CATCH)
(PM14)
PfD Bh
P
ro
f
.
D
.
B
usc
h
Dr H Stadler
Dr
.
H
.
Stadler
www.m4.de
Pro
j
ektziele
j
EntwicklungeinerbreitanwendbarenMethodezurIsolationspezifischerEntwicklungeinerbreitanwendbarenMethodezurIsolationspezifischer
Zell(sub)populationenauskomplexemAusgangsmaterial
Entwicklun
g
vollständi
g
reversibler Zellmarkierun
g
srea
g
enzien
Zell(sub)populationenauskomplexemAusgangsmaterial
Entwicklun
g
vollständi
g
reversibler Zellmarkierun
g
srea
g
enzien
g
g
gg
Entwicklung einer magnetfreien Zellisolierungstechnologie (CATCH)
g
g
gg
Entwicklung einer magnetfreien Zellisolierungstechnologie (CATCH)
minim
a
lm
a
ni
pu
li
e
rt
,
AnforderungenZellprodukt
ma
g
netfrei
AnforderungenZellisolierungstechnologie
p,
authentisch,freivonSelektionsreagenziensein
serielle Positivanreicherungen müssen möglich sein
g
kurzeIsolationszeiten
voll automatisierbar
serielle
Positivanreicherungen
müssen
möglich
sein
voll
automatisierbar
IsolierungausVollblutmöglich
www.m4.de
25
Page view 27
1 2 ... 23 24 25 26 27 28 29 30 31 32 33 ... 81 82

Comments to this Manuals

No comments